Discontinued — last reported Q3 '22
Regeneron Pharmaceuticals PP&E (Net) increased by 1.8% to $3.70B in Q3 2022 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $3.40B to $3.70B.
An increase indicates ongoing investment in physical capacity, whereas a decline may suggest aging assets or a strategy of asset-light operations.
This metric represents the book value of tangible assets after subtracting accumulated depreciation from the total histo...
Standard line item for all manufacturing and industrial companies; directly comparable across peers.
property_plant_equipment_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | |
|---|---|---|---|---|---|---|
| Value | $3.36B | $3.40B | $3.48B | $3.56B | $3.64B | $3.70B |
| QoQ Change | — | +1.1% | +2.5% | +2.1% | +2.3% | +1.8% |
| YoY Change | — | — | — | — | +8.3% | +9.1% |
| Segment | Q4 '22 |
|---|---|
| Rest Of World | $803.00M |
| Total | — |
Rest Of World was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q4 '24 | Q4 '25 |
|---|---|---|
| Outside United States | $715.90M | $788.00M |
| Total | — | — |